The Quantellect read.As of Nov 19, 2026, 5 active firms cover Editas Medicine Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $4.00 to $8.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $5.80 sits 226% above the current $1.78. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.20 next quarter toward $-0.73 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$5.80
+225.8% upside
Average target across 5 active firms as of Nov 19, 2026 vs $1.78 current
Highest Target$8.00
Average Target$5.80
Lowest Target$4.00
Detailed analyst forecasts for EDIT
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate EDIT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
EDIT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.20 – $-0.20 · 1 analysts · -23% YoY
Next period, 1 analysts expect Editas Medicine Inc to earn $-0.20 a share (range $-0.20 – $-0.20), versus $-0.26 a year earlier. Full-year consensus is $-0.75, growing to $-0.73 the year after.
REVENUE · NEXT QUARTER
$3.1M
Range $500.0K – $6.4M · 1 analysts · +11% YoY
Revenue is expected to reach $3.1M (range $500.0K – $6.4M), +10.7% year-over-year. Full-year consensus is $32.4M, rising to $20.7M next year.
Top analysts covering Editas Medicine Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EDIT.
#1
Joel Beatty
Baird · Rank #71
Buy
$6.00+237.1% to target
Overall win rate
50%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Neutral
$4.00+124.7% to target
Overall win rate
49%
+ Follow
#3
Brian Cheng
JP Morgan · Rank #87
Sell
No targeton EDIT
Overall win rate
51%
+ Follow
#4
Geulah Livshits
Chardan Capital · Rank #104
Buy
$4.00+124.7% to target
Overall win rate
43%
+ Follow
#5
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$5.00+180.9% to target
Overall win rate
39%
+ Follow
EDIT stock forecast FAQ
What is EDIT's average 12-month price target?+
The 5 active firms with a live target average $5.80 for Editas Medicine Inc over the next 12 months, ranging from a $8.00 high to a $4.00 low, as of Nov 19, 2026.
Is EDIT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for EDIT?+
The Street-high target is $8.00 (Jones Trading), and the Street-low is $4.00 (Chardan Capital). The average of all 5 active-firm targets is $5.80.
How many active Wall Street firms cover EDIT?+
5 active firms have a recognized rating on Editas Medicine Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering EDIT?+
Among analysts who currently cover EDIT, Joel Beatty of Baird has the strongest overall Quantellect track record (Rank #71). Their current call is Buy with a $6.00 target.
What is Editas Medicine Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.20 – $-0.20) across 1 analysts. Full-year EPS is projected at $-0.75, rising to $-0.73 the following year.
How much revenue is Editas Medicine Inc expected to report next quarter?+
Consensus revenue is $3.1M (range $500.0K – $6.4M). Full-year revenue is projected at $32.4M, growing to $20.7M next year.
Have analysts been upgrading or downgrading EDIT lately?+
As of Nov 19, 2026, 5 of 5 active firms rate EDIT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EDIT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.